Milestone says trial design trips up etripamil in tachycardia Phase III

Milestone’s at-home paroxysmal supraventricular tachycardia candidate did not meet its primary endpoint in the Phase III NODE-301 study, but the company believes the miss was due to trial

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE